Page 40 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $2.70
52wk Low $1.08 aTyr Pharma, Inc. LIFE $1.17
3545 John Hopkins Court
San Diego, CA 92121

(USD - in millions) www.atyrpharma.com
Market Cap 69.1
Enterprise (18.0)
Basic Shares Out. 58.56 COMPANY OVERVIEW
Float 48.32
Institutional Holdings 55.55% Detailed Analysis:Channelchek.com
Short Interest 0.23
Avg. 90-Day Volume 0.16 aTyr Pharma Inc is a biotherapeutics company, engaged in the
discovery and clinical development of medicines for patients suffering
from severe, rare diseases using its Physiocrine biology. It has
discovered approximately 300 Physiocrines, a class of naturally
EPS Data occurring human proteins that it promotes homeostasis, a fundamental
process of restoring stressed or diseased tissue to a healthier state.
2021 2022 2023 The company is developing Resolaris, an intravenous protein
CQ1 (0.51) (0.44) (0.29) therapeutic for the treatment of rare myopathies with an immune
CQ2 (0.64) (0.44) (0.22) component. Business activity is primarily conducted through the United
States.
CQ3 (0.42) (0.46) (0.20)
CQ4 (0.31) (0.26) (0.24)
CY (1.77) (1.60) (0.94) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 1.68
ROE (ttm) -49.27
Debt-to-Total Cap. (mrq) 13.42
Fiscal Year End 31-Dec

3545 John Ho San Diego CA 92121

Key Executives
CEO: Shukla, Sanjay
CFO: Broadfoot, Jill
COO: N/A
IR: Dunston, Ashlee
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures